The results of diethylstilboestrol therapy for recurrent and metastatic carcinoma of the male breast

Ribeiro, G

doi:10.1038/bjc.1976.72

Cited by 30 publications

(13 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several reports exist showing mild to moderate success with a variety of agents. Estrogen therapy in the form of diethylstilboestrol has been shown to have a 38%-40% total response rate when given to patients with advanced or recurrent male breast cancer [25,26]. Cyproterone acetate, a synthetic steroid with antiandrogenic and progestational activity has also shown success.…”

Section: Discussionmentioning

confidence: 99%

Successful use of letrozole in male breast cancer: A case report and review of hormonal therapy for male breast cancer

Zabolotny

Zalai

Meterissian

2005

Journal of Surgical Oncology

View full text Add to dashboard Cite

Male breast cancer is an uncommon occurrence. Treatment of male breast cancer is typically extrapolated from data on the treatment of female breast cancer. Recently, aromatase inhibition has been proven as an effective therapy for female breast cancer, particularly in the setting of advanced cancers. The efficacy of aromatase inhibitors in males, however, has not been established. We report the successful treatment of a male with locally advanced breast cancer using the aromatase inhibitor letrozole.

show abstract

Section: Discussionmentioning

confidence: 99%

Successful use of letrozole in male breast cancer: A case report and review of hormonal therapy for male breast cancer

Zabolotny

Zalai

Meterissian

2005

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…92,93 Given the often deleterious side effects of these ablative techniques, other means of hormonal manipulation have been tried with mild to moderate success reported. A variety of agents have been tested, such as estrogen therapy in the form of diethylstilbestrol, 95,96 cyproterone acetate (a synthetic steroid with anti androgenic and progestational activity), 97 medroxy progesterone acetate, 98 androgens, 94,95 and luteinizing-hormonereleasing hormone agonists, alone or in combination with anti androgens. 99,100 Because of the success of tamoxifen for treating both advanced MBC (responses ranged from 25-80%), 92,94,101 and as an adjuvant treatment (5-year diseasefree survival increased from 28% to 56%, and 5-year overall survival from 44% to 61%), 102 tamoxifen was incorporated as the mainstay of hormonal therapy in MBC.…”

Section: Hormonal Therapymentioning

confidence: 99%

Male breast cancer: a gender issue

Nahleh

Girnius

2006

Nat Rev Clin Oncol

View full text Add to dashboard Cite

The incidence of male breast cancer (MBC) is rising; however, mortality due to MBC has not changed, unlike female breast cancer. This lack of change is mostly attributable to a lack of major progress in the understanding and treatment of the disease. The treatment of MBC has been extrapolated from the knowledge of female breast cancer, despite the multiple differences in the pathogenesis, biology and genetics of these two disease entities, especially the differences with regard to the role of male hormones as well as estrogens in MBC compared with female disease. Although major advances in hormonal manipulation for the treatment of breast cancer are being developed, an improved understanding of the potential differences between male and female breast cancer is essential, as this would provide new opportunities for therapeutic intervention and probable improved outcome for MBC. This review aims at highlighting the major differences between male and female breast cancer with an emphasis on hormonal therapy, and discusses some of the recent advances in MBC.

show abstract

“…Although in a retrospective re view of 55 patients treated with diethylstilbestrol (DES), an overall response rate of 38% was reported [11], estrogens have been generally considered of lim ited usefulness for MBC [12], and exacerbation of the disease has sometimes occurred with these agents [13]. Our limited experience is somewhat better, with re gression of osseous and visceral metastases for 20 and 33 months in 2 of 5 cases treated with estrogenic compounds.…”

Section: Discussionmentioning

confidence: 86%

Hormonal Treatment of Disseminated Male Breast Cancer

et al. 1985

View full text Add to dashboard Cite

14 males with disseminated cancer of breast received a total of 35 endocrine trials, mainly in the form of hormonal supplementation. Overall, a 43% response rate was observed. In particular, remissions occurred in 7 of 11 instances with cyproterone acetate, in 3 of 7 with tamoxifen, in 2 of 5 with estrogens, in 2 of 5 with aminoglutethimide, in none of 3 with high-dose medroxyprogesterone acetate, in none of 1 with androgens, and in 1 of 3 with castration. The response to additive hormonal therapy was 44%. Median overall response duration was 10 months, 11 months following additive hormonal therapy. Median survival from start of therapy was longer in responding than in nonresponding patients (23.5 vs. 11 months). A disease-free interval did not appear to influence hormonal response. Patients responding to one form of hormonal treatment had a greater likelihood of responding to subsequent hormonal manipulations. Additive hormonal therapy may provide effective palliation in males with advanced breast cancer, and should be considered as a valid alternative to orchiectomy.

show abstract

The results of diethylstilboestrol therapy for recurrent and metastatic carcinoma of the male breast

Cited by 30 publications

References 5 publications

Successful use of letrozole in male breast cancer: A case report and review of hormonal therapy for male breast cancer

Successful use of letrozole in male breast cancer: A case report and review of hormonal therapy for male breast cancer

Male breast cancer: a gender issue

Hormonal Treatment of Disseminated Male Breast Cancer

Contact Info

Product

Resources

About